Please assess the completion status of the following clinical trial:

Trial Title: Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatient~2. Subjective complaint of dry eye that has been present for minimum 20 months~3. Ocular discomfort severity is moderate to severe~4. Corneal - conjunctival damage is moderate to severe~5. Unanesthetized Schirmer's test score of 5mm/5minutes or less~6. Best corrected visual acuity of 0.2 or better in both eyes~Exclusion Criteria:~1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca~2. Ocular hypertension patient or glaucoma patient with ophthalmic solution~3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study~4. Anticipated use of contact lens during the study~5. Patient with punctal plug~6. Any history of ocular surgery within 12 months~7. Female patients who are pregnant, possibly pregnant or breast feeding~8. Known hypersensitivity to any component of the study drug or procedural medications~9. Receipt of any investigational product within 4 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
- 1% OPC-12759 ophthalmic suspension (Type: EXPERIMENTAL): 1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
- 2% OPC-12759 ophthalmic suspension (Type: EXPERIMENTAL): 2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).